Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 211 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Beta adrenergic blockers Clear all
Completed No phase listed Observational Results available

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

NCT01099397
View directory record Official record
Conditions
Prediabetic State
Interventions
Oral glucose tolerance test
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

NCT01202175
View directory record Official record
Conditions
Pre-hypertension, Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation

NCT02132767
View directory record Official record
Conditions
Postoperative Atrial Fibrillation
Interventions
Amiodarone, DC-cardioversion, Rate Control
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 4 Interventional

Effects of Carvedilol on Health Outcomes in Heart Failure

NCT00381030
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
carvedilol plus nurse management
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
0 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 27, 2006 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

NCT02092428
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Image Quality, Diagnostic Accuracy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 13, 2026, 1:14 PM EDT
Recruiting Phase 2 Interventional

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

NCT04682158
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
Carboplatin, 3 Dimensional Conformal Radiation Therapy, Propranolol, Intensity Modulated Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Early Phase 1 Interventional

Regression of Myocardial Steatosis by Nebivolol

NCT01358409
View directory record Official record
Conditions
Cardiac Steatosis and Lipotoxicity
Interventions
Nebivolol
Drug
Lead sponsor
Lidia Szczepaniak
Other
Eligibility
18 Years to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 13, 2026, 1:14 PM EDT
Recruiting Phase 4 Interventional

The STOP-MED CTRCD Trial

NCT06183437
View directory record Official record
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions
Stopping Heart Failure Medication(s)
Other
Lead sponsor
Dinesh Thavendiranathan
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Not applicable Interventional

Get With the Guidelines in ED Patients With Heart Failure

NCT02519283
View directory record Official record
Conditions
Heart Failure
Interventions
GUIDED-HF, Standard of Care
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 13, 2026, 1:14 PM EDT
Terminated Not applicable Interventional

Syntrillo Telehealth Stroke Risk Reduction Study

NCT07124728
View directory record Official record
Conditions
Hypertension, Hypertension (HTN), Stroke Prevention, Cardiovascular Risk Factor
Interventions
Technology-enabled Telehealth Care Plan, Blood Pressure Monitoring Device, Tenovi Smart Pillbox, Wearable Activity Trackers (Fitbit or Apple Watch), Healthie EHR, Secure Messaging Platforms (TigerConnect, Weave, AirCall), Antihypertensive Medication Management, Statin Medication Management, Antiplatelet or Anticoagulant Therapy, Laboratory Blood Test Collection
Behavioral · Device · Other + 2 more
Lead sponsor
Syntrillo, Inc
Other
Eligibility
30 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril

NCT00657241
View directory record Official record
Conditions
Hypertension
Interventions
Carvedilol CR, Valsartan
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Occluded Artery Trial (OAT)

NCT00004562
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, Congestive, Heart Failure
Interventions
Beta adrenergic blockers, Platelet inhibitors, PTCA and stents, ACE Inhibitors
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Pilot - Peri-operative Beta Blockade

NCT02746575
View directory record Official record
Conditions
Adrenergic Beta-Receptor Blockader, Troponin Levels, Cardiomyopathy, Post-surgical
Interventions
metoprolol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
51 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 13, 2026, 1:14 PM EDT
Completed No phase listed Observational

The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure

NCT01971944
View directory record Official record
Conditions
Acute Decompensated Heart Failure, Heart Failure
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids

NCT01222091
View directory record Official record
Conditions
Hyperalgesia
Interventions
Propranolol, Placebo to Match Propranolol, Remifentanil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 13, 2026, 1:14 PM EDT
Terminated Phase 4 Interventional Results available

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

NCT05479123
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol three times a day, Propranolol twice a day, Timolol
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 18 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 13, 2026, 1:14 PM EDT
Recruiting No phase listed Observational

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
60
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 4 Interventional

Pulse Reduction On Beta-blocker and Ivabradine Therapy

NCT02973594
View directory record Official record
Conditions
Dilated Cardiomyopathies, Idiopathic, Heart Failure, Systolic, Ventricular Remodeling, Electrical Remodeling
Interventions
Ivabradine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 13, 2026, 1:14 PM EDT
Withdrawn Phase 4 Interventional

Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)

NCT04234477
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Beta-blocker strategy, Calcium channel blocker strategy, Physician preference strategy
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 13, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Propranolol Attenuate Inflammatory Responses to a Psychological Stressor?

NCT02972554
View directory record Official record
Conditions
Stress, Psychological, Inflammation, Cortisol, Sympathetic Nervous System
Interventions
Propanolol hydrochloride, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 13, 2026, 1:14 PM EDT